Table 2.

Upper gastrointestinal event rates by agent and relative safety of weekly risedronate compared with weekly alendronate

Outcome of Interest	Alendronate		Risedronate		Hazard ratio (95%CI)
	Events, n	Ratea	Events, n	Ratea	Unadjusted	P value	Adjustedb	P value
Hospitalization for upper gastrointestinal bleed	16	0.84	15	1.00	1.19 (0.59–2.40)	0.63	1.12 (0.55–2.28)	0.76
Upper gastrointestinal disease	612	34.26	508	36.10	1.05 (0.94–1.19)	0.39	0.95 (0.84–1.07)	0.41
Upper gastrointestinal symptom	662	37.26	516	36.70	0.99 (0.88–1.11)	0.80	0.96 (0.85–1.07)	0.45
Upper gastrointestinal endoscopy	134	7.13	90	6.05	0.85 (0.65–1.11)	0.23	0.82 (0.62–1.07)	0.142
Gastroprotective treatment	1,843	130.45	1,588	146.60	1.11 (1.04–1.19)	0.002	0.98 (0.92–1.05)	0.65
Switched between therapies	111	5.89	60	4.02	0.68 (0.50–0.93)	0.02	0.67 (0.49–0.92)	0.01
Any upper gastrointestinal diagnosis or procedure	1,058	62.31	867	64.87	1.04 (0.95–1.14)	0.39	0.98 (0.89–1.07)	0.61
Any upper gastrointestinal diagnosis or procedure, or gastroprotective treatment	2,263	170.71	1,920	189.90	1.10 (1.03–1.17)	0.003	0.99 (0.93–1.05)	0.75

Patients were censored on the date of death or 120 days after treatment initiation

CI confidence interval, HR hazard ratio

^aRate per 100 person-years of follow-up

^bAdjusted for risedronate propensity score quintiles as four dummy variables